Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

INTRODUCTION: This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing multiple sclerosis (RMS) after suboptimal response to glatiramer acetate (GA; “first switch” patients), including patients with early MS (“early...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neurol Ther
Main Authors: Repovic, Pavle, Robertson, Derrick, Kresa-Reahl, Kiren, Cohan, Stanley L., Su, Ray, Avila, Robin, Koulinska, Irene, Mendoza, Jason P.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2020
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140000/
https://ncbi.nlm.nih.gov/pubmed/33225410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-020-00223-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares